ArticleJTCVS structural and endovascular2026
Elective interval thoracic endovascular aortic repair versus medical management for uncomplicated type B aortic dissection among Medicare patients.
Article in JTCVS structural and endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare elective interval thoracic endovascular aortic repair (TEVAR) with ongoing medical management (MM) within 90 days for uncomplicated type B aortic dissection (uTBAD). Methods: Medicare MedPar files from 2001 to 2020 were queried for patients with acute uTBAD who were discharged after index hospitalization without operative intervention. The exposure was elective interval TEVAR versus MM within the first 90 days. Outcomes were overall survival, aortic reintervention, and reintervention-free survival. Propensity score matching, Kaplan-Meier analysis and Fine-Gray regression landmarking at 90 days were used. Results: In total, 23,697 patients were discharged without surgical intervention after admission for acute uTBAD. Within 90 days from diagnosis, 22,857 patients underwent MM, 399 elective TEVAR, and 441 emergent/urgent TEVAR. Matching between MM and elective TEVAR resulted in a well-balanced nearly 27:1 match with 10,608 patients in the MM cohort and 399 in the elective TEVAR cohort. The mean age was 73.5 years, and 51% of patients were female. 90-day mortality was 10.4% for MM and 4.3% for elective TEVAR. Landmarking at 90 days, there was no associated difference in overall survival with 5-year mortality of ∼63%. Similarly, there was no associated difference in reintervention-free survival. The 5-year cumulative incidence of aortic reintervention for MM was 11% and for TEVAR was 14% ( Conclusions: Among Medicare patients with acute uTBAD, there was no associated difference in overall survival or reintervention free survival between ongoing MM and elective interval TEVAR within 90 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.